Anorexia nervosa: A unified neurological perspective

International Journal of Medical Sciences

Volumn 8, Issue 8, 2011, Pages 679-703

  Hasan, Tasneem Fatema ^a   Hunaid, Hasan ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Anorexia nervosa; Corticotrophin releasing factor; Energy balance; Ghrelin; Leptin; Opioids peptide; Sex differences

Indexed keywords

AUTOANTIBODY; BETA ENDORPHIN; BETA LIPOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; DYNORPHIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FATTY ACID; GHRELIN; GHRELIN AUTOANTIBODY; GLUCOSE; GLYCOGEN; GONADORELIN; GONADOTROPIN; GROWTH HORMONE; HYDROCORTISONE; KAPPA OPIATE RECEPTOR; LEPTIN; MU OPIATE RECEPTOR; NEUROPEPTIDE Y; NOCICEPTIN; NOCICEPTIN RECEPTOR; OPIATE PEPTIDE; PROOPIOMELANOCORTIN; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG; UROCORTIN;

ADDICTION; ADRENERGIC STIMULATION; AMYGDALOID NUCLEUS; ANOREXIA NERVOSA; APPETITE; ARCUATE NUCLEUS; ARTICLE; BEHAVIOR; BINGE EATING PURGING TYPE ANOREXIA NERVOSA; BIOSYNTHESIS; BODY FAT; BODY IMAGE; BODY MASS; BONE MARROW FAT; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CLINICAL FEATURE; CONDITIONING; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DORSAL RAPHE NUCLEUS; ENERGY EXPENDITURE; ESTROGEN RECEPTOR 1 GENE; FEAR; FEAR CONDITIONING; FEEDING BEHAVIOR; FOOD INTAKE; GENE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HERITABILITY; HIPPOCAMPUS; HORMONE ACTION; HORMONE RELEASE; HORMONE RESISTANCE; HUMAN; HUNGER; HYPERCORTISOLISM; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEAN BODY WEIGHT; LOCUS CERULEUS; MENTAL HEALTH; MENTAL STRESS; NEUROPEPTIDE Y GENE; NOCICEPTIN GENE; NONHUMAN; NORADRENERGIC SYSTEM; OBESITY; OBSESSIVE COMPULSIVE DISORDER; PHYSICAL ACTIVITY; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN WASTING; PSYCHOLOGICAL ASPECT; RESTRICTIVE TYPE ANOREXIA NERVOSA; REWARD; REWARD RELATED BEHAVIOR; SEX DIFFERENCE; SLEEP; STARVATION; STRIA TERMINALIS; SURVIVAL;

EID: 80555145067     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8.679     Document Type: Article

References (335)

1. Kaplan HI, Sadock BJ. Synopsis of Psychiatry: Behavioral Sciences Clin-ical Psychiatry, 8th ed. Baltimore, USA: Williams & Wilkins; 1998.
2. Kaye WH. Neuropeptide abnormalities in anorexia nervosa. Psychiatry Res. 1996; 62: 65-74.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Press; 1994.
4. Eddy KT, Keel PK, Dorer DJ, et al. Longitudinal comparison of anorexia nervosa subtypes. Int J Eat Disord. 2002; 31: 191-201.
5. Foulon C, Guelfi JD, Kipman A, et al. Switching to the bingeing/purging subtype of anorexia nervosa is frequently associated with suicidal at-tempts. Eur Psychiatry. 2007; 22: 513-9.
6. Milos G, Spindler A, Hepp U, et al. Suicide attempts and suicidal idea-tion: links with psychiatric comorbidity in eating disorder subjects. Gen Hosp Psychiatry. 2004; 26: 129-35.
7. Morris J, Twaddle S. Anorexia nervosa. BMJ. 2007; 334: 894-8.
8. Hudson JI, Hiripi E, Pope Jr HG, et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007; 61: 348-58.
9. Ramoz N, Versini A, Gorwood P. Eating disorders: an overview of treatment responses and the potential impact of vulnerability genes and endophenotypes. Expert Opin Pharmacother. 2007; 8: 2029-44.
10. Harris EC, Barraclough BM. Suicide as an outcome for medical disor-ders. Medicine (Baltimore). 1994; 73: 281-96.
11. Hoek HW. Incidence, prevalence and mortality of anorexia nervosa and other eating disorders. Curr Opin Psychiatry. 2006; 19: 389-94.
12. Carter JC, Blackmore E, Sutandar-Pinnock K. Relapse in anorexia ner-vosa: a survival analysis. Psychol Med. 2004; 34: 671-9.
13. Talbot Y. Anorexia nervosa: a lifestyle disorder. Can Fam Physician. 1983; 29: 553-7.
14. Johnson JG, Cohen P, Kasen S, et al. Eating disorders during adolescence and the risk of physical and mental disorders during early adult-hood. Arch Gen Psychiatry. 2002; 59: 545-52.
15. Bulik CM, Sullivan PF, Tozzi F, et al. Prevalence, heritability, and pro-spective risk factors for anorexia nervosa. Arch Gen Psychiatry. 2006; 63: 305-12.
16. Klump KL, Miller KB, Keel PK, et al. Genetic and environmental influ-ences on anorexia nervosa syndromes in a population-based twin sam-ple. Psychol Med. 2001; 31: 737-40.
17. Kortegaard LS, Hoerder K, Joergensen J, et al. A preliminary popula-tion-based twin study of self-reported eating disorder. Psychol Med. 2001; 31: 361-5.
18. Mazzeo SE, Mitchell KS, Bulik CM, et al. Assessing the heritability of anorexia nervosa symptoms using a marginal maximal likelihood ap-proach. Psychol Med. 2009; 39: 463-73.
19. Wade TD, Bulik CM, Neale M, et al. Anorexia nervosa and major de-pression: shared genetic and environmental risk factors. Am J Psychia-try. 2000; 157: 469-71.
20. Gorwood P, Kipman A, Foulon C. The human genetics of anorexia nervosa. Eur J Pharmacol. 2003; 480: 163-70.
21. McCue MD. Starvation physiology: reviewing the different strategies animals use to survive a common challenge. Comp Biochem Physiol A Mol Integr Physiol. 2010; 156: 1-18.
22. Devlin MJ. Why does starvation make bones fat? Am J Hum Biol. 2011; 23: 577-85.
23. Anghel SI, Wahli W. Fat poetry: a kingdom for PPARg. Cell Res. 2007; 17: 486-511.
24. Guerre-Millo M, Rouault C, Poulain P, et al. PPAR-a-null mice are pro-tected from high-fat diet-induced insulin resistance. Diabetes. 2001; 50: 2809-14.
25. Kroetz DL, Yook P, Costet P, et al. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem. 1998; 273: 31581-9.
26. Inagaki T, Lin VY, Goetz R, et al. Inhibition of growth hormone signal-ling by the fasting-induced hormone FGF21. Cell Metab. 2008; 8: 77-83.
27. Fazeli PK, Bredella MA, Misra M, et al. Preadipocyte factor-1 is associ-ated with marrow adiposity and bone mineral density in women with anorexia nervosa. J Clin Endocrinol Metab. 2010; 95: 407-13.
28. Wang T, Hung CC, Randall DJ. The comparative physiology of food deprivation: from feast to famine. Annu Rev Physiol. 2006; 68: 223-51.
29. Dulloo AG, Jacquet J. An adipose-specific control of thermogenesis in body weight regulation. Int J Obes Relat Metab Disord. 2001; 25 (Suppl 5): S22-S29.
30. Ellison PT. Energetics and reproductive effort. Am J Hum Biol. 2003; 15: 342-51.
31. Prentice AM. Starvation in humans: evolutionary background and contemporary implications. Mech Ageing Dev. 2005; 126: 976-81.
32. Vale W, Rivier C, Brown MR, et al. Chemical and biological characteri-zation of corticotropin releasing factor. Recent Prog Horm Res. 1983; 39: 245-70.
33. Rivier CL, Plotsky PM. Mediation by corticotropin releasing factor (CRF) of adenohypophysial hormone secretion. Annu Rev Physiol. 1986; 48: 475-94.
34. Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corti-cotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci. 1995; 15: 6340-50.
35. Fisher LA. Central actions of corticotropin-releasing factor on autonomic nervous activity and cardiovascular functioning. In: Chadwick DJ, Marsh J, Ackrill K, eds. CIBA Foundation symposium on corticotro-pin-releasing factor. Chichester: Wiley; 1993: 243-57.
36. Koob GF, Heinrichs SC, Pich EM, et al. The role of corticotro-pin-releasing factor in behavioural responses to stress. In: Chadwick DJ, Marsh J, Ackrill K, eds. CIBA Foundation symposium on corticotro-pin-releasing factor. Chichester: Wiley. 1993: 277-95.
37. Spiess J, Rivier J, Rivier C, et al. Primary structure of corticotro-pin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci U S A. 1981; 78: 6517-21.
38. Vale W, Spiess J, Rivier C, et al. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and be-ta-endorphin. Science. 1981; 213: 1394-7.
39. Krahn DD, Gosnell BA, Majchrzak MJ. The anorectic effects of CRH and restraint stress decrease with repeated exposures. Biol Psychiatry. 1990; 27: 1094-102.
40. Aguilera G, Millan MA, Hauger RL, et al. Corticotropin-releasing factor receptors: distribution and regulation in brain, pituitary, and peripheral tissues. Ann N Y Acad Sci. 1987; 512: 48-66.
41. Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry. 1999; 46: 1167-80.
42. Dieterich KD, Lehnert H, De Souza EB. Corticotropin-releasing factor receptors: An overview. Exp Clin Endocrinol Diabetes. 1997; 105: 65-82.
43. Spiess J, Dautzenberg FM, Sydow S, et al. Molecular properties of the CRF receptor. Trends Endocrinol Metab. 1998; 9: 140-5.
44. Cullen MJ, Ling N, Fosterr AC, et al. Urocortin, corticotropin releasing factor-2 receptors and energy balance. Endocrinology. 2001; 142: 992-9.
45. Contarino A, Dellu F, Koob GF, et al. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. 1999; 835: 1-9.
46. Habib KE, Weld KP, Rice KC, et al. Oral administration of a corticotro-pin-releasing hormone receptor antagonist significantly attenuates be-havioral, neuroendocrine, and autonomic responses to stress in pri-mates. Proc Natl Acad Sci U S A. 2000; 97: 6079-84.
47. Heinrichs SC, Lapsansky J, Lovenberg TW, et al. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behaviour. Regul Pept. 1997; 71: 15-21.
48. Liebsch G, Landgraf R, Engelmann M, et al. Differential behavioral effects of chronic infusion of CRH1 and CRH2 receptor antisense oligo-nucleotides into the rat brain. J Psychiatr Res. 1999; 33: 153-63.
49. Lundkvist J, Chai Z, Teheranian R, et al. A non peptidic corticotro-pin-releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol. 1996; 309: 195-200.
50. Mansbach RS, Brooks EN, Chen YL. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol. 1997; 323: 21-6.
51. Skutella T, Probst JC, Renner U, et al. Cortocotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience. 1998; 85: 795-805.
52. Weninger SC, Dunn AJ, Muglia LJ, et al. Stress-induced behaviors re-quire the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Natl Acad Sci U S A. 1999; 96: 8283-8.
53. Smith GW, Aubry JM, Dellu F, et al. Corticotropin-releasing factor re-ceptor 1-deficient mice display decreased anxiety, impaired stress re-sponse, and aberrant neuroendocrine development. Neuron. 1998; 20: 1093-102.
54. Timpl P, Spanagel R, Sillaber I, et al. Impaired stress response and re-duced anxiety in mice lacking a functional corticotropin-releasing hor-mone receptor 1. Nat Genet. 1998; 19: 162-6.
55. Swanson LW, Sawchenko PE. Hypothalamic integration: organization of the paraventricular and supraoptic nuclei. Annu Rev Neurosci. 1983; 6: 269-324.
56. Antoni FA, Palkovits M, Makara GB, et al. Immunoreactive corticotro-pin-releasing hormone in the hypothalamoinfundibular tract. Neuro-endocrinology. 1983; 36: 415-23.
57. Kishimoto T, Pearse RV 2nd, Lin CR, et al. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci U S A. 1995; 92: 1108-12.
58. Kostich WA, Chen A, Sperle K, et al. Molecular identification and anal-ysis of a novel human corticotropin-releasing factor (CRF) receptor: The CRF2gamma receptor. Mol Endocrinol. 1998; 12: 1077-85.
59. Lovenberg TW, Liaw CW, Grigoriadis DE, et al. Cloning and character-ization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A. 1995; 92: 836-40.
60. Perrin M, Donaldson C, Chen R, et al. Identification of a second cortico-tropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A. 1995; 92: 2969-73.
61. Ho SP, Takahashi LK, Livanov V, et al. Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Brain Res Mol Brain Res. 2001; 89: 29-40.
62. Menard J, Treit D. Lateral and medial septal lesions reduce anxiety in the plus maze and probe-burying tests. Physiol Behav. 1996; 60: 845-53.
63. Yadin E, Thomas E, Grishkat HL, et al. The role of the lateral septum in anxiolysis. Physiol Behav. 1993; 53: 1077-83.
64. Sawchenko PE. Evidence for a local site of action for glucocorticoids in inhibiting CRF and vasopressin expression in the paraventricular nu-cleus. Brain Res. 1987; 403: 213-23.
65. Swanson LW, Sawchenko PE, Rivier J, et al. Organization of ovine cor-ticotropin-releasing factor immunoreactivity cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology. 1983; 36: 165-86.
66. Fischman AJ, Moldow RL. Extrahypothalamic distribution of CRF-like immunoreactivity in the rat brain. Peptides. 1982; 3: 149-53.
67. Merchenthaler I, Vigh S, Petrusz P, et al. Immunocytochemical localiza-tion of corticotropin-releasing factor (CRF) in the rat brain. Am J Anat. 1982; 165: 385-96.
68. Olschowka JA, O'Donohue TL, Mueller GP, et al. The distribution of corticotropin-releasing factor-like immunoreactive neurons in rat brain. Peptides. 1982; 3: 995-1015.
69. Phelps EA. Human emotion and memory: interactions of the amygdala and hippocampal complex. Curr Opin Neurobiol. 2004; 14: 198-202.
70. MacLean PD. Some psychiatric implications of physiological studies on frontotemporal portion of limbic system (visceral brain). Electroenceph-alogr Clin Neurophysiol. 1952; 4: 407-18.
71. Rivier C, Vale W. Influence of corticotropin-releasing factor on repro-ductive functions in the rat. Endocrinology. 1984; 114: 914-21.
72. Claes SJ. Trends in molecular medicine. Ann Med. 2004; 36: 50-61.
73. Brown MR, Fisher LA, Spiess J, et al. Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocri-nology. 1982; 111: 928-31.
74. Kalin NH, Shelton SE, Kraemer GW, et al. Corticotropin-releasing factor administered intraventricularly to rhesus monkeys. Peptides. 1983; 4: 217-20.
75. Muglia L, Jacobson L, Dikkes P, et al. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature. 1995; 373: 427-32.
76. Valentino RJ, Foote SL, Aston-Jones G. Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res. 1983; 270: 363-7.
77. Hashimoto K, Murakami K, Hattori T, et al. Corticotropin-releasing factor (CRF)-like immunoreactivity in the adrenal medulla. Peptides. 1984; 5: 707-11.
78. Suda T, Tomori N, Tozawa F, et al. Immunoreactive corticotropin and corticotropin-releasing factor in human hypothalamus, adrenal, lung cancer, and pheochromocytoma. J Clin Endocrinol Metab. 1984; 58: 919-24.
79. Petrusz P, Merchenthaler I, Maderdrut JL, et al. Central and peripheral distribution and corticotropin-releasing factor. Fed Proc. 1985; 44: 229-35.
80. Udelsman R, Harwood JP, Millan MA, et al. Functional corticotro-pin-releasing factor receptors in the primate peripheral sympathetic nervous system. Nature. 1986; 319: 147-50.
81. Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev. 2002; 26: 713-28.
82. Morley JE, Blundell JE. The neurobiological basis of eating disorders: some formulations. Biol Psychiatry. 1988; 23: 53-78.
83. Koneru A, Satyanarayana S, Rizwan S. Endogenous opioids: their phys-iological role and receptors. Global J Pharmacol. 2009; 3: 149-53.
84. Monteleone P. New frontiers in endocrinology of eating disorders. Curr Top Behav Neurosci. 2011; 6: 189-208.
85. Glass MJ, Billington CJ, Levine AS. Opioids and food intake: distributed functional neural pathways? Neuropeptides. 1999; 33: 360-8.
86. Kelley AE, Bakshi VP, Haber SN, et al. Opioid modulation of taste he-donics within the ventral striatum. Physiol Behav. 2002; 76: 365-77.
87. Will MJ, Franzblau EB, Kelley AE. Nucleus accumbens mu-opioids regulate intake of high-fat diet via activation of a distributed brain net-work. J Neurosci. 2003; 23: 2882-8.
88. Chabane N, Leboyer M, Mouren-Simeoni MC. Opiate antagonists in children and adolescents. Eur Child Adolesc Psychiatry. 2000; 9 (Suppl 1): I44-I50.
89. Sakata I, Nakamura K, Yamazaki M, et al. Ghrelin-producing cells exist as two types of cells, closed and opened-type cells, in the rat gastroin-testinal tract. Peptides. 2002; 23: 531-6.
90. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402: 656-60.
91. Müller TD, Perez-Tilve D, Tong J, et al. Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia. J Cachex Sarcope-nia Muscle. 2010; 1: 159-67.
92. Williams DL, Cummings DE. Regulation of ghrelin in physiologic and pathophysiologic states. J Nutr. 2005; 135: 1320-5.
93. Tschöp M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circu-lating human ghrelin levels. J Endocrinol Invest. 2001; 24: RC19-21.
94. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001; 50: 1714-9.
95. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001; 86: 4753-8.
96. Hosoda H, Kojima M, Mizushima T, et al. Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing. J Biol Chem. 2003; 278: 64-70.
97. Yang J, Zhao TJ, Goldstein JL, et al. Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci U S A. 2008; 105: 10750-5.
98. Gutierrez JA, Solenberg PJ, Perkins DR, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci U S A. 2008; 105: 6320-5.
99. Hillman JB, Tong J, Tschop M. Ghrelin biology and its role in weight-related disorders. Discov Med. 2011; 11: 521-8.
100. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996; 273: 974-7.
101. Miljic D, Pekic S, Djurovic M, et al. Ghrelin has partial or no effect on appetite, growth hormone, prolactin, and cortisol release in patients with anorexia nervosa. J Clin Endocrinol Metab. 2006; 91: 1491-5.
102. Cummings DE, Frayo RS, Marmonier C, et al. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab. 2004; 287: E297-304.
103. Kamegai J, Tamura H, Shimizu T, et al. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology. 2000; 141: 4797-800.
104. Kamegai J, Tamura H, Shimizu T, et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes. 2001; 50: 2438-43.
105. Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature. 2006; 443: 289-95.
106. Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001; 86: 1169-74.
107. Peino R, Baldelli R, Rodriguez-Garcia J, et al. Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol. 2000; 143: R11-4.
108. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab. 1993; 77: 1671-6.
109. Fuller J, Mynett JR, Sugden PH. Stimulation of cardiac protein synthesis by insulin-like growth factors. Biochem J. 1992; 282: 85-90.
110. Moller N, Vendelbo MH, Kampmann U, et al. Growth hormone and protein metabolism. Clin Nutr. 2009; 28: 597-603.
111. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocri-nology. 2000; 141: 4325-8.
112. Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001; 50: 2540-7.
113. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in ro-dents. Nature. 2000; 407: 908-13.
114. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001; 50: 227-32.
115. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001; 86: 5992.
116. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, place-bo-controlled trial. J Clin Endocrinol Metab. 2004; 89: 2832-6.
117. Hosoda H, Kojima M, Matsuo H, et al. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun. 2000; 279: 909-13.
118. Tolle V, Zizzari P, Tomasetto C, et al. In vivo and in vitro effects of ghrelin/motilin-related peptide on growth hormone secretion in the rat. Neuroendocrinology. 2001; 73: 54-61.
119. Zhang F, Basinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature. 1997; 387: 206-9.
120. Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006; 2: 318-27.
121. Margetic S, Gazzola C, Pegg GG, et al. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002; 26: 1407-33.
122. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Im-munol. 2005; 174: 3137-42.
123. Sinha MK, Ohannesian JP, Heiman ML, et al. Nocturnal rise of leptin in lean, obese, and non-insulin dependent diabetes mellitus subjects. J Clin Invest. 1996; 97: 1344-7.
124. Licinio J, Mantzoros C, Negrão AB, et al. Human leptin levels are pulsa-tile and inversely related to pituitary-adrenal function. Nat Med. 1997; 3: 575-9.
125. Bluher S, Mantzoros CS. Leptin in humans: lessons from translational research. Am J Clin Nutr. 2009; 89: 991S-997S.
126. Schwartz MW, Seeley RJ, Campfield LA, et al. Identification of targets of leptin action in rat hypothalamus. J Clin Invest. 1996; 98: 1101-6.
127. Grinspoon S, Gulick T, Askari H, et al. Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab. 1996; 81: 3861-3.
128. Dardeno TA, Chou SH, Moon HS, et al. Leptin in human physiology and therapeutics. Front Neuroendocrinol. 2010; 31: 377-93.
129. Boden G, Chen X, Mozzoli M, et al. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab. 1996; 81: 3419-23.
130. Chan JL, Heist K, DePaoli AM, et al. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003; 111: 1409-21.
131. Kiess W, Petzold S, Töpfer M, et al. Adipocytes and adipose tissue. Best Pract Res Clin Endocrinol Metab. 2008; 22: 135-53.
132. Rosenbaum M, Nicolson M, Hirsch J, et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab. 1996; 81: 3424-7.
133. Saad MF, Damani S, Gingerich RL, et al. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab. 1997; 82: 579-84.
134. Montague CT, Prins JB, Sanders L, et al. Depot- and sex-specific differ-ences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes. 1997; 46: 342-7.
135. Fei H, Okano HJ, Li C, et al. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci U S A. 1997; 94: 7001-5.
136. Lee GH, Proenca R, Montez JM, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature. 1996; 379: 632-5.
137. Bjørbaek C, Elmquist JK, Michl P, et al. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology. 1998; 139: 3485-91.
138. Hileman SM, Pierroz DD, Masuzaki H, et al. Characterization of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology. 2002; 143: 775-83.
139. Tartaglia LA. The leptin receptor. J Biol Chem. 1997; 272: 6093-6.
140. Elmquist JK, Bjørbaek C, Ahima RS, et al. Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol. 1998; 395: 535-47.
141. Baranowska B. Are disturbances in opioids and adrenergic systems involved in the hormonal dysfunction of anorexia nervosa? Psychoneu-roendocrinology. 1990; 15: 371-9.
142. Kaiyala KJ, Woods SC, Schwartz MW. New model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr. 1995; 62 (Suppl 5): 1123S-1134S.
143. Schwartz MW, Figlewicz DP, Baskin DG, et al. Insulin and the central regulation of the energy balance: update 1994. Endocrine Monogr Rev. 1994; 2: 109-13.
144. Campfield LA, Smith FJ, Burn P. The OB protein (leptin) pathway-- a link between adipose tissue mass and central neural networks. Horm Metab Res. 1996; 28: 619-32.
145. Seeley RJ, Matson CA, Chavez M, et al. Behavioral, endocrine, and hypothalamic responses to involuntary overfeeding. Am J Physiol. 1996. 271: R819-23.
146. Schlesser MA, Winokur G, Sherman BM. Hypothalam-ic-pituitary-adrenal axis activity in depressive illness. Its relationship to classification. Arch Gen Psychiatry. 1980; 37: 737-43.
147. Dunn AJ, Berridge CW. Physiological and behavioral responses to cor-ticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev. 1990; 15: 71-100.
148. Glowa JR, Gold PW. Corticotropin-releasing hormone produces pro-found anorexigenic effects in the rhesus monkey. Neuropeptides. 1991; 18: 55-61.
149. Arase K, York DA, Shimizu H, et al. Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats. Am J Physiol. 1988; 255: E255-9.
150. Morley JE, Levine AS. Corticotrophin-releasing factor, grooming and ingestive behavior. Life Sci. 1982; 31: 1459-64.
151. Bornstein SR, Webster EL, Torpy DJ, et al. Chronic effects of a nonpep-tide corticotropin-releasing hormone type I receptor antagonist on pitu-itary-adrenal function, body weight, and metabolic regulation. Endo-crinology. 1998; 139: 1546-55.
152. Buwalda B, de Boer S, Van Kalkeren AA, et al. Physiological and be-havioral effects of chronic intracerebroventricular infusion of corticotro-pin-releasing factor in the rat. Psychoneuroendocrinology. 1997; 22: 297-309.
153. Rivest S, Deshaies Y, Richard D. Effects of corticotropin-releasing factor on energy balance in rats are sex dependent. Am J Physiol. 1989; 257: R1417-22.
154. Rohner-Jeanrenaud F, Walker CD, Greco-Perotto R, et al. Central corti-cotropin-releasing factor administration prevents the excessive body weight gain of genetically obese (fa/fa) rats. Endocrinology. 1989; 124: 733-9.
155. Smagin GN, Howell LA, Ryan DH, et al. The role of CRF2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia. Neu-roreport. 1998; 9: 1601-6.
156. Donaldson CJ, Sutton SW, Perrin MH, et al. Cloning and characterization of human urocortin. Endocrinology. 1996; 137: 2167-70.
157. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 1995; 378: 287-92.
158. Bray GA. Regulation of energy balance: studies on genetic, hypothalamic and dietary obesity. Proc Nutr Soc. 1982; 41: 95-108.
159. Holt S, York DA. The effect of adrenalectomy on GDP binding to brown-adipose-tissue mitochondria of obese rats. Biochem J. 1982; 208: 819-22.
160. Romsos DR. Norepinephrine turnover in obese mice and rats. Int J Obes. 1985; 2 (Suppl 9): 55-62.
161. Saito M, Bray GA. Adrenalectomy and food restriction in the genetically obese (ob/ob) mouse. Am J Physiol. 1984; 246: R20-5.
162. Arase K, York DA, Bray GA. Corticosterone inhibition of the intracere-broventricular effect of 2-deoxy-D-glucose on brown adipose tissue thermogenesis. Physiol Behav. 1987; 40: 489-95.
163. Bray GA. Obesity-a disease of nutrient or energy balance? Nutr Rev. 1987; 45: 33-43.
164. Rivest S, Landry J, Richard D. Effects of exercise training on energy balance of orchidectomized rats. Am J Physiol. 1989; 257: R550-5.
165. Dunn AJ, Berridge CW. Corticotropin-releasing factor administration elicits a stress-like activation of cerebral catecholaminergic systems. Pharmacol Biochem Behav. 1987; 27: 685-91.
166. Emoto H, Tanaka M, Koga C, et al. Corticotropin-releasing factor acti-vates the noradrenergic neuron system in the rat brain. Pharmacol Bio-chem Behav. 1993; 45: 419-22.
167. Lavicky J, Dunn AJ. Corticotropin-releasing factor stimulates catechol-amine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis. J Neurochem. 1993; 60: 602-12.
168. Matsuzaki I, Takamatsu Y, Moroji T. The effects of intracerebroventric-ularly injected corticotropin-releasing factor (CRF) on the central nerv-ous system: behavioral and biochemical studies. Neuropeptides. 1989; 13: 147-55.
169. Jezova D, Ochedalski T, Glickman M, et al. Central corticotro-pin-releasing hormone receptors modulate hypothalam-ic-pituitary-adrenocortical and sympathoadrenal activity during stress. Neuroscience. 1999; 94: 797-802.
170. Korte SM, Bouws GA, Bohus B. Central actions of corticotropin-releasing hormone (CRH) on behavioral, neuroendocrine, and cardiovascular regulation: brain corticoid receptor involvement. Horm Behav. 1993; 27: 167-83.
171. Linthorst AC, Flachskamm C, Hopkins SJ, et al. Long-term intracere-broventricular infusion of corticotropin-releasing hormone alters neu-roendocrine, neurochemical, autonomic, behavioural and cytokine re-sponses to a systemic inflammatory challenge. J Neurosci. 1997; 17: 4448-60.
172. Pacak K, Tjurmina O, Palkovits M, et al. Chronic hypercortisolemia inhibits dopamine synthesis and turnover in the nucleus accumbens: an in vivo microdialysis study. Neuroendocrinology. 2002; 76: 148-57.
173. Radulovic J, Rühmann A, Liepold T, et al. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci. 1999; 19: 5016-25.
174. Shors TJ, Weiss C, Thompson RF. Stress-induced facilitation of classical conditioning. Science. 1992; 24: 537-9.
175. Roozendaal B, Brunson KL, Holloway BL, et al. Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. Proc Natl Acad Sci U S A. 2002; 99: 13908-13.
176. Sananbenesi F, Fischer A, Schrick C, et al. Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotro-pin-releasing factor receptor 2: a possible link between stress and fear memory. J Neurosci. 2003; 23: 11436-43.
177. Kandel ER. The molecular biology of memory storage: a dialogue be-tween genes and synapses. Science. 2001; 294: 1030-8.
178. Matynia A, Anagnostaras SG, Silva AJ. Weaving the molecular and cognitive strands of memory. Neuron. 2001; 32: 557-9.
179. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neu-rochem. 2001; 76: 1-10.
180. Pedersen WA, Wan R, Zhang P, et al. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J Neuro-sci. 2002; 22: 404-12.
181. Radulovic M, Hippel C, Spiess J. Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases. J Neurochem. 2003; 84: 1074-85.
182. Rossant CJ, Pinnock RD, Hughes J, et al. Corticotropin-releasing factor type 1 and type 2alpha receptors regulate phosphorylation of calci-um/cyclic adenosine 3',5'-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase. Endocrinology. 1999; 140: 1525-36.
183. Hammack SE, Schmid MJ, LoPresti ML, et al. Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the be-havioral consequences of uncontrollable stress. J Neurosci. 2003; 23: 1019-25.
184. Chen Y, Brunson KL, Müller MB, et al. Immunocytochemical distribu-tion of corticotropin-releasing hormone receptor type-1 (CRF(1))-like immunoreactivity in the mouse brain: light microscopy analysis using an antibody directed against the C-terminus. J Comp Neurol. 2000; 420: 305-23.
185. Van Pett K, Viau V, Bittencourt JC, et al. Distribution of mRNAs encod-ing CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol. 2000; 428: 191-212.
186. De Souza EB, Insel TR, Perrin MH, et al. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci. 1985; 5: 3189-203.
187. [Internet] Severance K. An introduction to dopamine. http://www.macalester.edu/psychology/whathap/UBNRP/Dopamine/intro.html
188. Heinrichs SC, Menzaghi F, Pich EM, et al. Corticotropin-releasing factor in the paraventricular nucleus modulates feeding induced by neuropep-tide Y. Brain Res. 1993; 611: 18-24.
189. Brady LS, Smith MA, Gold PW, et al. Altered expression of hypothalamic neuropeptide mRMAs in food-restricted and food-deprived rats. Neu-roendocrinology. 1990; 52: 441-7.
190. Haas DA, George SR. Neuropeptide Y administration acutely increases hypothalamic corticotropin-releasing factor immunoreactivity: lack of effect in other rat brain regions. Life Sci. 1987; 41: 2725-31.
191. Härfstrand A. Brain neuropeptide Y mechanisms. Basic aspects and involvement in cardiovascular and neuroendocrine regulation. Acta Physiol Scand Suppl. 1987; 565: 1-83.
192. Morley JE. Neuropeptide regulation of appetite and weight. Endocr Rev. 1987; 8: 256-87.
193. Krahn DD, Gosnell BA, Levine AS, et al. Behavioural effects of cortico-tropin-releasing factor: localization and characterization of central ef-fects. Brain Res. 1988; 443: 63-9.
194. Pich EM, Messori B, Zoli M, et al. Feeding and drinking responses to neuropeptide Y injections in the paraventricular hypothalamic nucleus of aged rats. Brain Res. 1992; 575: 265-71.
195. Morley JE, Levine AS, Gosnell BA, et al. Effect of neuropeptide Y on ingestive behaviours in the rat. Am J Physiol. 1987; 252: R599-609.
196. Stanley BG, Leibowitz SF. Neuropeptide Y injected in the paraventricu-lar hypothalamus: a powerful stimulant of feeding behavior. Proc Natl Acad Sci U S A. 1985; 82: 3940-3.
197. Kalra SP, Dube MG, Kalra PS. Continuous intraventricular infusion of neuropeptide Y evokes episodic food intake in satiated female rats: ef-fects of adrenalectomy and cholecystokinin. Peptides. 1988; 9: 723-8.
198. Stanley BG, Lanthier D, Chin AS, et al. Suppression of neuropeptide Y-elicited eating by adrenalectomy or hypophysectomy: reversal with corticosterone. Brain Res. 1989; 501: 32-6.
199. Beck B, Jhanwar-Uniyal M, Burlet A, et al. Rapid and localized altera-tions of neuropeptide Y in discrete hypothalamic nuclei with feeding status. Brain Res. 1990; 528: 245-9.
200. Kalra SP, Dube MG, Sahu A, et al. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci U S A. 1991; 88: 10931-5.
201. Sahu A, Kalra PS, Kalra SP. Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventric-ular nucleus. Peptides. 1988; 9: 83-6.
202. Hubner HF. Endorphins, eating disorders, and other addictive behav-iours. New York, USA: WW Norton & Company; 1993.
203. Abbate-Daga G, Amianto F, Rogna L, et al. Do anorectic men share personality traits with opiate dependent men? A case-control study. Addict Behav. 2007; 32: 170-4.
204. Marrazzi MA, McQuarters A, Barnes C et al. Male/female comparison of morphine effect on food intake-relation to anorexia nervosa. Pharmacol Biochem Behav. 1996; 53: 433-5.
205. Kaye WH. Neuropeptide abnormalities. In: Halmi KA, ed. Psychobiol-ogy and treatment of anorexia nervosa and bulimia nervosa. Washington DC: American Psychiatric Press; 1992: 169-91.
206. Kaye WH, Berrettini WH, Gwirtsman HE, et al. Reduced cerebrospinal fluid levels of immunoreactive pro-opiomelanocortin related peptides (including beta-endorphin) in anorexia nervosa. Life Sci. 1987; 41: 2147-55.
207. Kaye WH, Pickar D, Naber D, et al. Cerebrospinal fluid opioid activity in anorexia nervosa. Am J Psychiatry. 1982; 139: 643-5.
208. Gerner RH, Sharp B. CSF beta-endorphin-immunoreactivity in normal, schizophrenic, depressed, manic and anorexic subjects. Brain Res. 1982; 237: 244-7.
209. Brambilla F, Ferrari E, Petraglia F, et al. Peripheral opioid secretory pattern in anorexia nervosa. Psychiatry Res. 1991; 39: 115-27.
210. Tepper R, Weizman A, Apter A et al. Elevated plasma immunoreactive beta-endorphin in anorexia nervosa. Clin Neuropharmacol. 1992; 15: 387-91.
211. Lamberts SW, de Lange SA, Stefanko SZ. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. J Clin Endocrinol Metab. 1982; 54: 286-91.
212. Wilkes MM, Watkins WB, Stewart RD, et al. Localization and quantita-tion of beta-endorphin in human brain and pituitary. Neuroendocri-nology. 1980; 30: 113-21.
213. Glass MJ, Billington CJ, Levine AS. Feeding induced by food deprivation is differentially reduced by opioid receptor antisense oligodeoxynucleo-tide probes in rats. Brain Res. 2003; 987: 223-32.
214. Ciccocioppo R, Cippitelli A, Economidou D, et al. Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin-releasing factor to in-hibit its anorectic effect. Physiol Behav. 2004; 82: 63-8.
215. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995; 377: 532-5.
216. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuro-peptide that activates an opioid-like G protein-coupled receptor. Science. 1995; 270: 792-4.
217. Ciccocioppo R, Fedeli A, Economidou D, et al. The bed nucleus is a neuroanatomical substrate for the anorectic effect of corticotro-pin-releasing factor and for its reversal by nociceptin/orphanin FQ. J Neurosci. 2003; 23: 9445-51.
218. Köster A, Montkowski A, Schulz S, et al. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci U S A. 1999; 96: 10444-9.
219. Davis C, Claridge G. The eating disorders as addiction: a psychobiolog-ical perspective. Addict Behav. 1998; 23: 463-75.
220. Bergh C, Södersten P. Anorexia nervosa, self-starvation and the reward of stress. Nat Med. 1996; 2: 21-2.
221. Casper RC. Behavioral activation and lack of concern, core symptoms of anorexia nervosa? Int J Eat Disord. 1998; 24: 381-93.
222. Harada T, Nakahara T, Yasuhara D, et al. Obestatin, acyl ghrelin, and des-acyl ghrelin responses to an oral glucose tolerance test in the re-stricting type of anorexia nervosa. Biol Psychiatry. 2008; 63: 245-7.
223. Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol. 2001; 145: 669-73.
224. Nakahara T, Harada T, Yasuhara D, et al. Plasma obestatin concentra-tions are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. Biol Psychiatry. 2008; 64: 252-5.
225. Germain N, Galusca B, Grouselle D, et al. Ghrelin/obestatin ratio in two populations with low bodyweight: constitutional thinness and anorexia nervosa. Psychoneuroendocrinology. 2009; 34: 413-9.
226. Prince AC, Brooks SJ, Stahl D, et al. Systematic review and meta-analysis of the baseline concentrations and physiologic responses of gut hor-mones to food in eating disorders. Am J Clin Nutr. 2009; 89: 755-65.
227. Otto B, Tschöp M, Frühauf E, et al. Postprandial ghrelin release in ano-rectic patients before and after weight gain. Psychoneuroendocrinology. 2005; 30: 577-81.
228. Haas V, Onur S, Paul T, et al. Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery. Am J Clin Nutr. 2005; 81: 889-96.
229. Tolle V, Kadem M, Bluet-Pajot MT, et al. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab. 2003; 88: 109-16.
230. Nakai Y, Hosoda H, Nin K, et al. Short-term secretory regulation of the active form of ghrelin and total ghrelin during an oral glucose tolerance test in patients with anorexia nervosa. Eur J Endocrinol. 2004; 150: 913-4.
231. Nedvidkova J, Krykorkova I, Bartak V, et al. Loss of meal-induced de-crease in plasma ghrelin levels in patients with anorexia nervosa. J Clin Endocrinol Metab. 2003; 88: 1678-82.
232. Yi CX, Heppner K, Tschöp MH. Ghrelin in eating disorders. Mol Cell Endocrinol. 2011; 340: 29-34.
233. Boyar RM, Hellman LD, Roffwarg H, et al. Cortisol secretion and me-tabolism in anorexia nervosa. N Engl J Med. 1977; 296: 190-3.
234. Licinio J, Wong ML, Gold PW. The hypothalamic-pituitary-adrenal axis in anorexia nervosa. Psychiatry Res. 1996; 62: 75-83.
235. Croxson MS, Ibbertson HK. Low serum triiodothyronine (T3) and hy-pothyroidism in anorexia nervosa. J Clin Endocrinol Metab. 1977; 44: 167-74.
236. Starkey TA, Lee RA. Menstruation and fertility in anorexia nervosa. Am J Obstet Gynecol. 1969; 105: 374-9.
237. Eckert ED, Pomeroy C, Raymond N, et al. Leptin in anorexia nervosa. J Clin Endocrinol Metab. 1998; 83: 791-5.
238. Counts DR, Gwirtsman H, Carlsson LM, et al. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insu-lin-like growth factors (IGFs), and the IGF-binding proteins. J Clin En-docrinol Metab. 1992; 75: 762-7.
239. Stoving RK, Veldhuis JD, Flyvbjerg A, et al. Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregu-larity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J Clin Endocrinol Metab. 1999; 84: 2056-63.
240. Suda AK, Pittman CS, Shimizu T, et al. The production and metabolism of 3,5,3-triiodothyronine and 3,3,5-triiodothyronine in normal and fast-ing subjects. J Clin Endocrinol Metab. 1978; 47: 1311-9.
241. O'Brian JT, Bybee DE, Burman KD, et al. Thyroid hormone homeostasis in states of relative caloric deprivation. Metabolism. 1980; 29: 721-7.
242. Monteleone P, Serritella C, Martiadis V, et al. Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. J Clin Endocrinol Metab. 2008; 93: 4418-21.
243. Germain N, Galusca B, Le Roux CW, et al. Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide 1, ghrelin, and leptin. Am J Clin Nutr. 2007; 85: 967-71.
244. Golden NH, Kreitzer P, Jacobson MS, et al. Disturbances in growth hormone secretion and action in adolescents with anorexia nervosa. J Pediatr. 1994; 125: 655-60.
245. Argente J, Caballo N, Barrios V, et al. Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: effect of short- and long-term weight recupera-tion. J Clin Endocrinol Metab. 1997; 82: 2084-92.
246. Støving RK, Flyvbjerg A, Frystyk J, et al. Low serum levels of free and total insulin-like growth factor I (IGF-I) in patients with anorexia nervosa are not associated with increased IGF-binding protein-3 proteolysis. J Clin Endocrinol Metab. 1999; 84: 1346-50.
247. Misra M, Miller KK, Bjornson J, et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab. 2003; 88: 5615-23.
248. Terashi M, Asakawa A, Harada T, et al. Ghrelin reactive autoantibodies in restrictive anorexia nervosa. Nutrition. 2011; 27: 407-13.
249. Hotta M, Ohwada R, Akamizu T, et al. Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study. Endocr J. 2009; 56: 1119-28.
250. Broglio F, Gianotti L, Destefanis S, et al. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clin Endocrinol (Oxf). 2004; 60: 592-9.
251. Miljic D, Djurovic M, Pekic S, et al. Glucose metabolism during ghrelin infusion in patients with anorexia nervosa. J Endocrinol Invest. 2007; 30: 771-5.
252. Zhao TJ, Liang G, Li RL, et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci U S A. 2010; 107: 7467-72.
253. Weikel JC, Wichniak A, Ising M, et al. Ghrelin promotes slow-wave sleep in humans. Am J Physiol Endocrinol Metab. 2003; 284: E407-15.
254. Dzaja A, Dalal MA, Himmerich H, et al. Sleep enhances ghrelin levels in healthy subjects. Am J Physiol Endocrinol Metab. 2004; 28: E963-7.
255. Spiegel K, Rasali E, Penev P, et al. Brief communication: Sleep curtail-ment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004; 141: 846-50.
256. Van Cauter E, Latta F, Nedeltcheva A, et al. Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res. 2004; 14 (Suppl A): S10-7.
257. Arora S, Anubhuti. Role of neuropeptides in appetite regulation and obesity. Neuropeptides. 2006; 40: 375-401.
258. Morrison CD. Leptin signaling in brain: A link between nutrition and cognition? Biochim Biophys Acta. 2009; 1792: 401-8.
259. Ste Marie L, Miura GI, Marsh DJ, et al. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci U S A. 2000; 97: 12339-44.
260. Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Na-ture. 2001; 411: 480-4.
261. Myers MG, Cowley MA, Münzberg H, et al. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008; 70: 537-56.
262. Rogge G, Jones D, Hubert GW, et al. CART peptides: regulators of body weight, reward and other functions. Nat Rev Neurosci. 2008; 9: 747-58.
263. Ollmann MM, Wilson BD, Yang YK, et al. Antagonism of central mela-nocortin receptors in vitro and in vivo by agouti-related protein. Science. 1997; 278: 135-8.
264. Stanley BG, Leibowitz SF. Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci. 1984; 35: 2635-42.
265. Gao Q, Horvath TL. Neuronal control of energy homeostasis. FEBS Lett. 2008; 582: 132-41.
266. Leshan RL, Björnholm M, Münzberg H, et al. Leptin receptor signaling and action in the central nervous system. Obesity (Silver Spring). 2006; 14 (Suppl 5): 208S-212S.
267. Dhillon H, Zigman JM, Ye C, et al. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron. 2006; 49: 191-203.
268. Abizaid A, Gao Q, Horvath TL. Thoughts for food: brain mechanisms and peripheral energy balance. Neuron. 2006; 51: 691-702.
269. Casanueva FF, Dieguez C, Popovic V, et al. Serum immunoreactive leptin concentrations in patients with anorexia nervosa before and after partial weight recovery. Biochem Mol Med. 1997; 60: 116-20.
270. Herpertz S, Albers N, Wagner R, et al. Longitudinal changes of circadian leptin, insulin and cortisol plasma levels and their correlation during refeeding in patients with anorexia nervosa. Eur J Endocrinol. 2000; 142: 373-9.
271. Stoving RK, Vinten J, Handberg A, et al. Diurnal variation of the serum leptin concentration in patients with anorexia nervosa. Clin Endocrinol (Oxf). 1998; 48: 761-8.
272. Ferron F, Considine RV, Peino R, et al. Serum leptin concentrations in patients with anorexia nervosa, bulimia nervosa and non specific eating disorders correlate with the body mass index but are independent of the respective disease. Clin Endocrinol (Oxf). 1997; 46: 289-93.
273. Mathiak K, Gowin W, Hebebrand J, et al. Serum leptin levels, body fat deposition, and weight in females with anorexia or bulimia nervosa. Horm Metab Res. 1999; 31: 274-7.
274. Holtkamp K, Hebebrand J, Mika C, et al. High serum leptin levels sub-sequent to weight gain predict renewed weight loss in patients with an-orexia nervosa. Psychoneuroendocrinology. 2004; 29: 791-7.
275. Mantzoros C, Flier JS, Lesem MD, et al. Cerebrospinal fluid leptin in anorexia nervosa: correlation with nutritional status and potential role in resistance to weight gain. J Clin Endocrinol Metab. 2006; 82: 1845-51.
276. Holtkamp K, Herpertz-Dahlmann B, Mika C, et al. Elevated physical activity and low leptin levels co-occur in patients with anorexia nervosa. J Clin Endocrinol Metab. 2003; 88: 5169-74.
277. Van Elburg AA, Kas MJ, Hillebrand JJ, et al. The impact of hyperactivity and leptin on recovery from anorexia nervosa. J Neural Transm. 2007; 114: 1233-7.
278. Charpenet G, Tache Y, Forest MG, et al. Effects of chronic intermittent immobilization stress on rat testicular androgenic function. Endocri-nology. 1981; 109: 1254-8.
279. Guezennec CY, Ferre P, Serrurier B, et al. Effects of prolonged physical exercise and fasting upon plasma testosterone level in rats. Eur J Appl Physiol Occup Physiol. 1982; 49: 159-68.
280. Rivier C, Rivier J, Vale W. Stress-induced inhibition of reproductive functions: role of endogenous corticotropin-releasing factor. Science. 1986; 231: 607-9.
281. Dagnault A, Richard D. Involvement of the medial preoptic area in the anorectic action of estrogens. Am J Physiol. 1997; 272: R311-7.
282. Bao AM, Hestiantoro A, Van Someren EJ, et al. Colocalization of corti-cotropin-releasing hormone and oestrogen receptor-alpha in the para-ventricular nucleus of the hypothalamus in mood disorders. Brain. 2005; 128: 1301-13.
283. Versini A, Ramoz N, Le Strat Y, et al. Estrogen receptor 1 gene (ESR1) is associated with restrictive anorexia nervosa. Neuropsychopharmacolo-gy. 2010; 35: 1818-25.
284. Santollo J, Wiley MD, Eckel LA. Acute activation of ER alpha decreases food intake, meal size, and body weight in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol. 2007; 293: R2194-201.
285. Clipperton AE, Spinato JM, Chernets C, et al. Differential effects of estrogen receptor alpha and beta specific agonists on social learning of food preferences in female mice. Neuropsychopharmacology. 2008; 33: 2362-75.
286. Gindoff PR, Ferin M. Endogenous opioids peptides modulate the effect of corticotropin-releasing factor on gonadotropin release in the primate. Endocrinology. 1987; 121: 837-42.
287. Petraglia F, Sutton S, Vale W, et al. Corticotropin-releasing factor de-creases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circu-lation. Endocrinology. 1987; 120: 1083-8.
288. Petraglia F, Vale W, Rivier C. Opioids act centrally to modulate stress-induced decrease in luteinizing hormone in the rat. Endocrinolo-gy. 1986; 119: 2445-50.
289. Hervey E, Hervey GR. The influence of sex hormones on energy balance. In: Cioffi LA, James WPT, Van Itallie TB, eds. The body weight regula-tory system: normal and disturbed mechanisms. New York: Raven; 1981: 345-52.
290. Himms-Hagen J. Thermogenesis in brown adipose tissue as an energy buffer. Implications for obesity. N Engl J Med. 1984; 311: 1549-58.
291. LeFeuvre RA, Rothwell NJ, Stock MJ. Activation of brown fat thermo-genesis in response to central injection of corticotropin-releasing hor-mone in the rat. Neuropharmacology. 1987; 26: 1217-21.
292. Lofti M, MacDonald IA, Stock MJ. Energy losses associated with ov-en-drying and the preparation of rat carcasses for analysis. Br J Nutr. 1976; 36: 305-9.
293. Richard D. Effects of ovarian hormones in energy balance and brown adipose tissue thermogenesis. Am J Physiol. 1986; 250: R245-9.
294. Wade GN, Gray JM, Bartness TJ. Gonadal influences on adiposity. Int J Obes. 1985; 1 (Suppl 9): 83-92.
295. Eckel LA. Estradiol: a rhythmic, inhibitory, indirect control of meal size. Physiol Behav. 2004; 82: 35-41.
296. Varma M, Chai JK, Meguid MM, et al. Effect of estradiol and progester-one on daily rhythm in food intake and feeding patterns in Fischer rats. Physiol Behav. 1999; 68: 99-107.
297. Geary N, Asarian L, Sheahan J, et al. Estradiol-mediated increases in the anorexia induced by intraperitoneal injection of bacterial lipopolysac-charide in female rats. Physiol Behav. 2004; 82: 251-61.
298. Geary N. Estradiol, CCK and satiation. Peptides. 2001; 22: 1251-63.
299. Miller KK, Grieco KA, Klibanski A. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab. 2005; 90: 1428-33.
300. Rothwell NJ, Stock MJ. Energy balance and brown fat in adrenalecto-mized male, female, and castrated male rats. Metabolism. 1986; 35: 657-60.
301. Leal AM, Moreira AC. Daily variation of plasma testosterone, andros-tenedione, and corticosterone in rats under food restriction. Horm Be-hav. 1997; 31: 97-100.
302. Craft RM. Sex differences in opioid analgesia: "from mouse to man". Clin J Pain. 2003; 19: 175-86.
303. Intebi AD, Garau L, Brusco I, et al. Alzheimer's disease patients display gender dimorphism in circulating anorectic adipokines. Neuroim-munomodulation. 2003; 10: 351-8.
304. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Supportive Care Cancer. 2000; 8: 175-9.
305. Gayle DA, Desai M, Casillas E, et al. Gender-specific orexigenic and anorexigenic mechanisms in rats. Life Sci. 2006; 79: 1531-6.
306. Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 1996; 97: 2152-7.
307. Sarraf P, Frederich RC, Turner EM, et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med. 1997; 185: 171-5.
308. Abiko Y, Suzuki H, Masaoka T, et al. Enhanced plasma ghrelin levels in Helicobacter pylori-colonized, interleukin-1-receptor type 1-homozygous knockout (IL-1R1-/-) mice. World J Gastroenterol. 2005; 11: 4148-53.
309. Hotta M, Shibasaki T, Masuda A, et al. The responses of plasma adre-nocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa pa-tients. J Clin Endocrinol Metab. 1986; 62: 319-24.
310. Kaada, BR. Stimulation and regional ablation of the amygdaloid complex with reference to functional representations. In: Eleftheriou BE, ed. The Neurobiology of the Amygdala. New York: Plenum Press; 1972: 205-81.
311. [Internet] Alison Preston. Scientific American. How does short-term memory work in relation to long-term memory? Are short-term daily memories somehow transferred to long-term storage while we sleep? Revised September 2007. http://www.scientificamerican.com/article.cfm?id=experts-short-term-memory-to-long-term
312. Grossman A, Gaillard RC, McCartney P, et al. Opiate modulation of the pituitary-adrenal axis: effects of stress and circadian rhythm. Clin En-docrinol (Oxf). 1982; 17: 279-86.
313. Lane HC, Masur H, Edgar LC, et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983; 309: 453-8.
314. [Internet] Locus Coeruleus. http://www.caam.rice.edu/~cox/wrap/locuscoeruleus.pdf
315. Bossu C, Galusca B, Normand S, et al. Energy expenditure adjusted for body composition differentiates constitutional thinness from both nor-mal subjects and anorexia nervosa. Am J Physiol Endocrinol Metab. 2007; 292: E132-7.
316. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001; 409: 194-8.
317. Seeley RJ, van Dijk G, Campfield LA, et al. Intraventricular leptin re-duces food intake and body weight of lean rats but not obese Zucker rats. Horm Metab Res. 1996; 28: 664-8.
318. Mistry AM, Swick AG, Romsos DR. Leptin rapidly lowers food intake and elevates metabolic rates in lean and ob/ob mice. J Nutr. 1997; 127: 2065-72.
319. Willesen MG, Kristensen P, Rømer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology. 1999; 70: 306-16.
320. Mercer JG, Hoggard N, Williams LM, et al. Coexpression of leptin re-ceptor and preproneuropeptide Y mRNA in arcuate nucleus of mouse hypothalamus. J Neuroendocrinol. 1996; 8: 733-5.
321. Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 1995; 377: 530-2.
322. Tschöp M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50: 707-9.
323. De Souza MJ, Leidy HJ, O'Donnell E, et al. Fasting ghrelin levels in physically active women: relationship with menstrual disturbances and metabolic hormones. J Clin Endocrinol Metab. 2004; 89: 3536-42.
324. Holtkamp K, Mika C, Grzella I, et al. Reproductive function during weight gain in anorexia nervosa. Leptin represents a metabolic gate to gonadotropin secretion. J Neural Transm. 2003; 110: 427-35.
325. Norman RL. Corticotropin-releasing hormone effects on luteinizing hormone and cortisol secretion in intact female rhesus macaques. Biol Reprod. 1994; 50: 949-55.
326. Hamrick MW. Leptin, bone mass, and the thrifty phenotype. J Bone Miner Res. 2004; 19: 1607-11.
327. Hamrick MW, Della-Fera MA, Choi YH, et al. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in lep-tin-deficient ob/ob mice. J Bone Miner Res. 2005; 20: 994-1001.
328. Hamrick MW, Della Fera MA, Choi YH, et al. Injections of leptin into rat ventromedial hypothalamus increase adipocyte apoptosis in peripheral fat and in bone marrow. Cell Tissue Res. 2007; 327: 133-41.
329. Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for self-eating. Cell Death Differ. 2005; 12 (Suppl 2): 1542-52.
330. Chakrabarti P, English T, Shi J, et al. Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. Diabetes. 2010; 59: 775-81.
331. Syed FA, Oursler MJ, Hefferanm TE, et al. Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Os-teoporos Int. 2008; 19: 1323-30.
332. Yakar S, Rosen CJ, Bouxsein ML, et al. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabo-lism. FASEB J. 2009; 23: 709-19.
333. Levine M. Prevention of Eating Problems with Elementary Children. US: USA Today (July 1998). 1998.
334. [Internet] Kaplan, Brian. Provocative Therapy FAQs. http://drkaplan.co.uk/provocative-therapy-practice/faqs-provocative-therapy
335. Hasan H, Hasan TF. Laugh yourself into a healthier person: a cross cultural analysis of the effects of varying levels of laughter on health. Int J Med Sci. 2009; 6: 200-11.